Exploring the safety of anti-TNF biologics for rheumatic patients with occult hepatitis B infection and evidence-based management strategies.
Exploring non-anti-TNF biologics as salvage therapy for refractory acute severe ulcerative colitis, including vedolizumab, ustekinumab, and novel small molecule therapies.